BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/350/0.1/21.06.24 | Delayed Deutsche Boerse AG 07:54:05 2024-06-18 EDT | ||
| 11.52 EUR | -3.19% |
|
| Current month | +25.93% | ||
| 1 month | +34.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 11.52 | -3.19% |
| 24-06-17 | 11.9 | -4.65% |
| 24-06-14 | 12.48 | +2.63% |
| 24-06-13 | 12.16 | +2.10% |
| 24-06-12 | 11.91 | -3.64% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 07:54 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM5M3H |
| ISIN | DE000VM5M3H5 |
| Date issued | 2023-11-16 |
| Strike | 350 $ |
| Maturity | 2024-06-21 (3 Days) |
| Parity | 10 : 1 |
| Emission price | 3.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.71 € |
|---|---|
| Lowest since issue | 3.15 € |
| Spread | 0.12 € |
| Spread % | 1.04% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Warrants
- Warrant
